HCA Holdings Inc.
Thesis
HCA is well-positioned to benefit from significant industry tailwinds, particularly from the growing Medicare eligible population, which is expected to increase at a CAGR of ~3.0% over the next 20 years. The company's strong free cash flow allows for opportunistic share repurchases, and management has already returned $7 billion to shareholders, highlighting their commitment to returning capital. Additionally, health care reform is expected to reduce the number of unprofitable uninsured patients, potentially adding $1 billion in EBITDA over the next two years.
Did it work?
No price performance data is available and the time elapsed since the pitch is unknown, so the return cannot be weighed against the long direction. The thesis rests on structural tailwinds (Medicare population growth, buybacks) plus a specific catalyst of ~$1B in EBITDA from health care reform over two years, but there is no evidence provided confirming or refuting that these events played out. Without either price data or confirmation of the thesis events, no verdict on success or failure can be rendered.